Navigation Links
It's Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer
Date:9/11/2007

PARAMUS, N.J., Sept. 11 /PRNewswire-USNewswire/ -- If you have or have ever had chronic heartburn, you may be at risk for Barrett's esophagus, a serious complication of chronic, severe gastroesophageal reflux disease (GERD). Barrett's esophagus has been recognized as a major risk factor for developing cancer of the esophagus, the seventh deadliest cancer in men in the United States.

Barrett's esophagus is marked by cellular changes in the lining of the esophagus, which can progress to low-grade, and then high-grade dysplasia -- a level that is highly pre-malignant. These abnormal cellular changes can lead to a type of cancer called esophageal adenocarcinoma, the fastest rising malignancy in the United States, according to the National Institutes of Health.

The Valley Hospital's Center for Barrett's Esophagus and GERD provides cutting-edge diagnostic, treatment, management, and research services for these related conditions. The Center is one of the most comprehensive on the East Coast and unique to northern New Jersey. The physician team includes board-certified gastroenterologists and thoracic surgeons.

Diagnostic and treatment methods available at the Center include endoscopy, medications to reduce acid, minimally invasive surgical procedures to repair hiatal hernias and to prevent acid reflux, radiofrequency ablation to destroy abnormal cells, endoscopic mucosal resection to remove nodules within Barrett's esophagus, and esophageal cancer surgery.

Robert J. Korst, M.D., Medical Director of The Valley Hospital's Daniel and Gloria Blumenthal Cancer Center, and Director of Thoracic Surgery, says he and physicians at the Center for Barrett's Esophagus and GERD must take a two-prong approach to treating Barrett's esophagus that both destroys the abnormal lining and stops acid reflux.

"Radiofrequency ablation can get rid of the lining, but if the GERD is not controlled, those abnormal cells can grow back and put the patient at
'/>"/>

SOURCE The Valley Hospital
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials
5. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
8. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
9. Santaris Pharma Presents Positive Clinical Data on SPC2996 in Chronic Lymphocytic Leukaemia
10. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
11. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2008)... Nektar Therapeutics present preliminary Phase II ...ia in intubated and mechanicall... /- Bayer HealthCare,togeth...y presented positive,preliminary Phase II data on ...le at the American Thoracic Society (ATS) annual m...
(Date:5/19/2008)...Be Presented at the 2008 Annual European Congress ...Against Rheumatism (EULAR) -, - Initiation of Pha... of 2008 -, SAN D...iences, Inc.,(Nasdaq: RDEA ) today announced the ...or the treatment of patients with gout, RDEA594. G...
(Date:5/19/2008)..., May 19 /- IPSOGEN SA (Marseille and...arkets molecular diagnostic,assays for blood & bre...,the University of Texas MD Anderson Cancer Center...two studies on the Genomic Grade index (GGi) at th... to June 3, 2008. The data,indicate that the Genom...
(Date:5/18/2008)...a Demonstrated Higher Overall Maintenance of Heale...rsus Placebo --, SAN DIEGO, May 18 /...results from three pivotal Phase 3 studies evaluat...proton pump inhibitor (PPI),with an innovative dua...with erosive esophagitis (EE) and in maintenance o...
Breaking Medicine Technology:Amikacin Inhale Shows Promising Results in Phase II Study 2Amikacin Inhale Shows Promising Results in Phase II Study 3Amikacin Inhale Shows Promising Results in Phase II Study 4Amikacin Inhale Shows Promising Results in Phase II Study 5Amikacin Inhale Shows Promising Results in Phase II Study 6Amikacin Inhale Shows Promising Results in Phase II Study 7Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 2Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 3Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 4Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 5Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer 2Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer 3Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer 4TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis 2TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis 3TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis 4Breakthrough in Pulmonary Drug Delivery will Bring Numerous In Hospital Treatments to the Home 8547 1Breakthrough in Pulmonary Drug Delivery will Bring Numerous In Hospital Treatments to the Home 8547 2LineaGen Inc Launches With Close of 245 8 Million Series A Funding Round 2302 1LineaGen Inc Launches With Close of 245 8 Million Series A Funding Round 2302 2LineaGen Inc Launches With Close of 245 8 Million Series A Funding Round 2302 3LineaGen Inc Launches With Close of 245 8 Million Series A Funding Round 2302 4Possible New Way to Detect Monitor Liver Disease Without Painful Liver Biopsy 2297 1Possible New Way to Detect Monitor Liver Disease Without Painful Liver Biopsy 2297 2Skatepark injuries can incur economic pain 8540 1Skatepark injuries can incur economic pain 8540 2
...-(BUSINESS WIRE)--Apr 13, 2007 - Point Therapeutic... presentation of,preclinical data at the 2007 Annu...Research (AACR) taking place in Los Angeles,Calif...tions report,on preclinical studies on talabostat,...or the AACR presentations are as,follows: , Presen...
...GO--(BUSINESS WIRE)--Apr 13, 2007 - Ascenta Therap...le portfolio of,apoptosis-triggering compounds wil...ral poster presentations at next week,s 2007,Annua...esearch,(AACR), to be held in Los Angeles, Califor... been selected for presentation at the,"High Impac...
Other Medicine Technology:Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting 2Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting 3Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting 4Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting 5Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting 6
(Date:5/20/2008)...alth care problem all over the world, with 130 mil...nt is expensive and has variable results according... land mark in treatment is the virus clearance at ...onse (ETR), but many of the patients achieving the...us, the goal of treatment is to have persistent vi...
(Date:5/20/2008)...erless prescription use yields practical guides fo...nd policy makers, WASHINGTON, MAY 20 /PRNewswire-...eHI) and the Center for Improving Medication Manag... anticipated report detailing the,impact of electr...,consumers, employers, health plans and policy mak...
(Date:5/20/2008)...APOLIS, May 20 /PRNewswire/ -- On May 25, one brig...Honda, will be racing to win,the Indianapolis 500 ...s --,Eyes on the Road. By emblazoning their car on...tp://www.eyesontheroad.org, IndyCar owners Jay Pe...s driver, IndyCar Series,veteran Tomas Scheckter o...
(Date:5/20/2008)...nhaling long, thin carbon nanotubes may result in,...ewswire-USNewswire/ -- A major study published,tod... carbon nanotubes -- a,poster child for the "nanot...bestos if inhaled in sufficient quantities., The ...types of,nanotubes have the potential to cause mes...
Breaking Medicine News(10 mins):Health News:eHealth Initiative and the Center for Improving Medication Management to Present Report Detailing Both Impact of E-Prescriptions on U.S. Health Care System and Guidelines for Achieving Optimal Results 2Health News:eHealth Initiative and the Center for Improving Medication Management to Present Report Detailing Both Impact of E-Prescriptions on U.S. Health Care System and Guidelines for Achieving Optimal Results 3Health News:Luczo Dragon IndyCar Carries 'Eyes on the Road' Logo to Prevent Blindness to Indy 500 2Health News:Carbon Nanotubes That Look Like Asbestos, Behave Like Asbestos 2Health News:Carbon Nanotubes That Look Like Asbestos, Behave Like Asbestos 3Health News:Carbon Nanotubes That Look Like Asbestos, Behave Like Asbestos 4
...ly of enzymes called sirtuins, which can dramatica..., worms, and flies. Now, a new study from scienti...tegy for activating sirtuins to unleash their anti...o control age-associated metabolic disorders, incl...
... professor in Indiana University Bloomington's Dep...ome tips to help parents of teenagers have a conve...ge is the most difficult phase in the process of g...tegral part of this mind-boggling time. The resear...
... Biotech have been developing a harmless virus as ...accumulating data that suggests in addition to dir...the immune system to mount a separate, powerful an... Evidence for this theory has been mounting for ...
...cal journal The Lancet claims that a newer class o...his research carried out by Merck employees was co...dently. Patients suffering from arthritis general...s (NSAIDS) like Aspirin and ibuprofen. Ulcers and ...
Other Medicine News:Health News:Anti-Aging Powers of Enzyme Sirtuins 2Health News:Scientists Develop a Harmless Multi-Tasking Reovirus 2
Siemens Webcast: Expert Insight - Key Elements for a Successful Electrophysiology Program
...LEXILOG antimony pH catheters are designed for pat...ll catheters are number marked at 5cm intervals an...en individual models are available spanning most c...se or multi-use models with one or two sensors., ...
...limline multi-use catheters are designed using est...ution with the following benefits:, ,Working with...res where the multi-use catheter is used the Helli...n.,NOTE: ,Medtronic pH measurement systems have be...
FLEXILOG spare part.
Medicine Products: